# Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

> **NCT04156698** · PHASE2 · UNKNOWN · sponsor: **Eye & ENT Hospital of Fudan University** · enrollment: 51 (estimated)

## Conditions studied

- Hypopharyngeal Carcinoma
- Immunotherapy
- Chemotherapy

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04156698
- **Lead sponsor:** Eye & ENT Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-21
- **Primary completion:** 2023-04-16
- **Final completion:** 2026-01-16
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04156698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04156698, "Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04156698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*